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Emicizumab prophylaxis to facilitate anticoagulant therapy for 
management of intra‐atrial thrombosis in severe haemophilia 
with an inhibitor
A 6‐year‐old boy with severe haemophilia A and high‐titre inhibitor 
(peak 41.8 Bethesda units [BU]), undergoing immune tolerance induc-
tion (ITI) with high dose (~120 units/kg/d) extended half‐life recom-
binant factor VIII (FVIII) (recombinant Fc fusion protein) developed 
central venous access device (CVAD)‐associated bacteremia. For 
prophylaxis while on ITI, he had been receiving 1‐2× daily activated 
prothrombin complex concentrate (aPCC, 100 units/kg/dose) prophy-
laxis, with recombinant factor VIIa (rFVIIa, 200 μg/kg/dose) for break-
through bleeds via a port CVAD. During evaluation for his bacteremia, 
an echocardiogram revealed a “mobile target” at the end of his port in 
the right atrium (Figure 1 for clinical timeline). His port was removed, 
and a peripherally inserted central catheter (PICC) was placed.
A new port was placed, and 6 months later, he was admitted with 
recurrent bacteremia. A repeat echocardiogram demonstrated the 
thrombus, which measured 1.7 × 1.4 cm in size. Follow‐up echocar-
diograms demonstrated the mass to be stable in size. During the ad-
mission for port removal, he was found to have a negative Bethesda 
titre and sufficient FVIII recovery, but did not meet criteria for tol-
erance given continued short half‐life. Given this, and concerns for 
thrombus exacerbation, aPCC was discontinued. A follow‐up echo-
cardiogram 3 months later demonstrated decreasing thrombus size 
to 0.6 × 0.4 cm. Given partial reabsorption and lack of symptoms, the 
decision was made to continue observation with scheduled echocar-
diograms. Six months later, he developed recurrent hemarthroses 
into his left ankle in the context of an inhibitor titre of 17.5 BU and 
prophylactic daily aPCC was resumed. Three months later, echocar-
diogram showed a marginal increase in thrombus size. He was moni-
tored with serial echocardiograms over the next year with no change.
He continued to have intermittent hemarthroses and required one 
hospitalization for intensive infusions with alternating aPCC (85 units/
kg/dose) and rFVIIa (120 µg/kg/dose) every 6 hours. An echocar-
diogram demonstrated significant enlargement of the thrombus to 
2.4 × 1.4 cm, with new extension towards the tricuspid valve annu-
lus, and 9‐10 mm Hg gradient across the tricuspid valve. The patient 
reported a week long history of intermittent fatigue, dizziness and 
diaphoresis with minimal exertion. The severity of his symptomatic 
obstruction to right ventricular inflow and large mobile thrombus was 
an indication for surgical thrombectomy on cardiopulmonary bypass 
(CPB). Percutaneous options for intervention were considered and not 
thought to be viable. He was hospitalized, and all infusions through 
his port discontinued. It was presumed that the thrombus progression 
was likely attributable to continued use of bypassing agent therapy. 
We hypothesized that prophylaxis with emicizumab would allow hae-
mostatic control of bleeding yet result in a less procoagulant balance 
compared to prior bypassing therapy prophylaxis. He began treatment 
at the standard loading dose of 3 mg/kg subcutaneously weekly for 
4 weeks followed by maintenance dosing of 1.5 mg/kg weekly. Upon 
transition to maintenance dosing, a repeat echocardiogram revealed 
no change in thrombus size. Therefore, formal anticoagulation was 
initiated with twice daily low molecular weight heparin (LMWH) at 
a goal anti‐Xa of 0.3‐0.5 IU/mL (typical goals 0.1‐0.3 IU/mL prophy-
lactic dosing, and 0.5‐1 IU/mL treatment dosing) to first evaluate his 
bleeding risk. After 4 days, there was no change on repeat echocar-
diogram yet he was not having any bleeding manifestations, so his 
anti‐Xa target was increased to 0.5‐0.7 IU/mL. Following 2 weeks of 
anticoagulation, the thrombus appeared slightly smaller in size and 
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increasingly organized, thus this management plan was continued. The 
patient continued to tolerate anticoagulation well without significant 
bleeding symptoms. He developed one spontaneous haematoma on 
his upper arm but otherwise had only expected bruises at injection 
sites. Following 2 months of anticoagulation, a repeat echocardiogram 
demonstrated significant improvement. The thrombus had decreased 
in size to 1.5 × 1.1 cm and was less mobile, the mean inflow gradient 
had decreased to 3‐5 mm Hg from 12 mm Hg previously, and there 
was improved motion of tricuspid valve leaflets. Additionally, he had 
symptomatic improvement with decreased heart rate and improved 
activity tolerance. Following 3 months of anticoagulation, his port was 
removed. Prior to removal, he continued emicizumab (but received a 
one‐time higher dose of 3 mg/kg prior to surgery under the rationale 
that this may provide improved haemostasis) and his LMWH was held 
for 24 hours prior to the procedure. He did not require additional hae-
mostatic agents during removal and tolerated the procedure well with-
out any bleeding. LMWH was restarted 24 hours postremoval, and he 
continued with therapeutic anticoagulation levels and no bleeding 
symptoms. Repeat echocardiogram performed 2 weeks later demon-
strated stable thrombus. He received 6 months of anticoagulation. 
Follow‐up echocardiogram 3 months after discontinuation of antico-
agulation demonstrated continued improvement with increasing orga-
nization of the thrombus. The patient has remained on emicizumab for 
routine prophylaxis without any need for bypassing agent treatment.
Central venous access devices are commonly needed in the treat-
ment of children with haemophilia, particularly those undergoing ITI. The 
most common complication of CVADs in patients with haemophilia is 
infection, with rates of 0.66/1000 catheter days. Thrombosis has his-
torically been reported to be much less common, with an incidence rate 
of 0.056 per 1000 catheter days as derived from a meta‐analysis of 48 
studies.1 These rates are likely an underestimate of the true prevalence 
as prospective screening studies have found CVAD‐associated throm-
bosis in up to 81% of patients, although the majority are subclinical in 
nature.2 These studies emphasize the asymptomatic, chronic course of 
most CVAD‐associated thrombosis in haemophilia patients, the major-
ity of which do not require treatment. Thrombosis risk may be higher in 
patients with inhibitors receiving ITI given the potential for synergy be-
tween an indwelling catheter, high dose FVIII and bypassing agents.3 Our 
patient had all of these along with the additional risk factors of recurrent 
infections and multiple line replacement procedures. He did not have ad-
ditional risk factors such as obesity, family history of thrombosis or other 
thrombophilic risk factors. Co‐administration of aPCC and rFVIIa likely 
contributed to this patient‘s thrombosis. This strategy has efficacy for re-
fractory inhibitor patients, but must be used with caution. The availability 
of emicizumab may provide opportunities to avoid it altogether.
No evidence‐based guidelines exist for the use of anticoagulation 
in patients with inherited bleeding disorders. Few cases have been 
described in the literature in paediatric haemophilia and catheter‐as-
sociated thrombosis, as patients typically are treated with catheter 
removal. The need for anticoagulation more commonly occurs in the 
treatment of adults with haemophilia given comorbidities including 
atrial fibrillation and atherothrombosis. The patient‘s bleeding pheno-
type influences anticoagulation considerations. This is particularly dif-
ficult in the case of a patient with an inhibitor, as ~10%‐20% of bleeds 
may not fully respond to treatment with bypassing agents (BPAs).4 As 
such, the risk of uncontrollable bleeding often outweighs the bene-
fits of anticoagulation in this population. Despite our patient‘s severe 
bleeding phenotype with concurrent inhibitor, the critical nature and 
associated symptoms of his thrombosis demanded treatment. Initially, 
consideration was given to surgical thrombectomy as that would be 
the recommendation in a non‐haemophilic patient, but ultimately an-
ticoagulation was deemed to be a safer alternative. Serendipitously, 
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the approval of emicizumab occurred shortly before our patient‘s 
thrombosis progressed. Systemic anticoagulation with concomitant 
emicizumab has not been previously described. The availability of emi-
cizumab provided multiple benefits in this situation. Some literature 
suggests that trough levels of >10%‐15% should be targeted prior to 
anticoagulation.5 Recent data in patients on emicizumab prophylaxis 
reports FVIII activity by human reagent chromogenic assay to reach 
~20 IU/dL by week 5.6 Data from HAVEN 1 and 2, two of the pivotal 
clinical trials for emicizumab approval, clearly demonstrate decreased 
bleeding rates with use of emicizumab in haemophilia A with inhibi-
tors compared to those on prophylaxis with BPAs.7,8 Additionally, its 
subcutaneous mode of administration allowed discontinuation of fur-
ther procoagulant infusions through the port. The choice of LMWH 
was made based on its safety and efficacy in children, ease of labora-
tory monitoring, and lower bleeding risk compared to warfarin.9
Consideration of surgical thrombectomy raised many questions 
regarding appropriate laboratory monitoring. Classically, hepariniza-
tion during bypass procedures is monitored using activated clotting 
times (ACTs), a point of care, contact activated whole blood coagu-
lation test. Little is known about the effects of emicizumab on ACT 
although the prescribing information reports interference. Further 
complicating the situation, we were unable to obtain baseline ACT 
data on our patient given the need for urgent anticoagulation and 
possible effects of LMWH on ACT. There is very little in the liter-
ature about CPB in patients with haemophilia, and all cases except 
one10 that have been reported have been in non‐inhibitor patients. 
Fortuitously, our patient responded to anticoagulation and the need 
for CPB was obviated. This case demonstrates effective bleed con-
trol, as well as continued improvement in thrombosis and associated 
symptomatology with concurrent anticoagulation and emicizumab. 
The dose of emicizumab was increased prior to surgery, which would 
lead to a higher peak level, though there is no data to support in-
creased efficacy with this approach. No additional haemostatic ther-
apy was required for port removal in the presence of therapeutic 
emicizumab. Although this particular scenario is rare, its real‐life 
efficacy data in these types of settings will help inform emicizumab 
use, which is critical given its expanding indications.
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